Bronchodilating effects of cumulative doses of formoterol from a novel multi-dose inhaler (airmax®)

Respiratory Medicine

Volumn 97, Issue 1, 2003, Pages 71-74

  Dubois, E F L ^a   Roder E ^a   Ifle R G ^b  

^a REINIER DE GRAAF HOSPITAL   (Netherlands)

^b NONE

Author keywords

Asthma; Cumulative doses; Dry powder inhaler; Formoterol; Multi dose inhaler; Single dose inhaler

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; FORMOTEROL FUMARATE; SALBUTAMOL;

ADULT; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INCIDENCE; MALE; METERED DOSE INHALER; POWDER INHALER; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0344089368     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1410     Document Type: Review

References (15)

1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroids. Lancet 1994; 344: 219-224.
2. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1998; 337:15 405-15 411.
3. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during one year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-1043.
4. Derom EY, Pauwels PA. Time course of bronchodilating effect of inhaled formoterol, a potent and long-acting sympathomimetic. Thorax 1992; 47: 30-33.
5. Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993;48: 611-614.
6. Zeng XM, O'Leary D, Phelan M, Jones S, Colledge J. Delivery of salbutamol and of budesonide from a novel multi dose inhaler Airmax®. Respir Med 2002; 96(6): 404-411.
7. Zeng XM, Jones S, O'Leary D, Phelan M, Colledge J. Delivery of formoterol from a novel multi dose inhaler Airmax®. Respir Med 2002; 96(6): 397-403.
8. Chew NY, Chan HK. In vitro aerosol performance and dose uniformity between the Foradil Aerolizer and the Oxis Turbuhaler. J Aerosol med 2001, 14(4): 495-501.
9. Maesen FPV, Costongs R, Smeets SJ, Zweers PGMA, Goedhart DM. Formoterol as dry powder inhalation; a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; 101: 1376-1381.
10. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med 1998; 92: 1017-1021.
11. Shenfield G, Paterson J. Clinical assessment of bronchodilator drugs delivered by aerosol. Thorax 1973; 28: 124.
12. Duncan D, Paterson I, Harris D, Crompton G. Comparison of the effects of salbutamol inhaled as a dry powder and by conventional pressurized aerosol. Br J Clin Pharmacol 1977; 4: 669-671.
13. Foucard T, Lönnerholm G. A study with cumulative doses of formoterol and salbutamol in children with asthma. Eur Respir J 1991; 4: 1174-1177.
14. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall, J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Resp J 1997; 10: 2484-2489.
15. Wallin A, Sandstrom T, Rosenhall L, Melander, B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611-614.